NCT06218290View on ClinicalTrials.gov

A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis

PHASE2CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

May 29, 2024

Study Completion Date

May 29, 2024

Conditions

Chronic Kidney Disease Requiring Chronic Dialysis

Interventions

DRUG

Oxylanthanum Carbonate

Phosphate Binder to Reduce Hyperphosphatemia

Trial Locations (7)

14215

US Renal Care, Cheektowaga

33912

US Renal Care, Fort Myers

43613

US Renal Care, Toledo

71603

US Renal Care, Pine Bluff

78211

US Renal Care, San Antonio

78212

Clinical Advancement Center, PLLC, San Antonio

87301

US Renal Care, Gallup

All Listed Sponsors

lead

Unicycive Therapeutics, Inc

INDUSTRY

NCT06218290 - A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis | Biotech Hunter | Biotech Hunter